A Study of Treprostinil to Treat Interstitial Lung Disease Pulmonary Hypertension

Overview

About this study

The purpose of this study is to see if patients with Pulmonary Arterial Hypertension related to Interstitial Lung Disease (ILD-PAH) will have impaired cardiac output reserve and leg blood flow during exercise, and inhlaed treprostinil will acutely increase exertional leg blood flow and cardiac output with preserved skeletal muscle O2 uptake efficiency, and to see a baseline hemodynamic improvement in exertional cardiac output with inhaled treprostinil will predict subsequent NYHA class improvement at 3 months with chronic inhaled treprostinil therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Patients with Pulmonary Arterial Hypertension due to Interstitial Lung Disease (ILD-PAH) being considered for inhaled treprostinil.
  • Resting right heart catheterization wi.mean pulmonary artery pressure > 20 mmHg and PVR > 3 Wood units.
  • Healthy volunteers will have no known lung disease, heart failure, muscular disease or pulmonary hypertension, no bleeding abnormalities, and have the ability to exercise.

Exclusion Criteria:

  • Inability to exercise.
  • Females who are pregnant.

Eligibility last updated 4/20/23. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yogesh Reddy, M.B.B.S.

Closed for enrollment

Contact information:

Circulatory Failure Research Team

(507) 255-2200

More information

Publications

Publications are currently not available